Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of Manufacturing and Other Contingent Milestone and Co-Development Payments

The Company is also subject to certain contingent milestone payments, disclosed in the following table, payable to the Company’s manufacturer of its nebulizer used to administer Molgradex. In addition to these milestones, the Company will owe a royalty to the manufacturer of its nebulizer based on net sales. The royalty rate ranges from three and a half percent (3.5%) to five percent (5%) depending on the device technology used by the Company to administer the product.

Manufacturing and Other Contingent Milestone and Co-Development Payments (in thousands):

	September 30, 2018
Molgradex API manufacturer:
Delivery of working and master cell banks	$	600
Achievement of certain milestones related to    regulatory approval of Molgradex		2,000
Molgradex nebulizer manufacturer:
Achievement of various development activities and    regulatory approval of nebulizer utilized to administer    Molgradex		8,062
Molgradex (aPAP) Japanese licensee:
Co-development and regulatory costs		750
Total manufacturing and other commitments	$	11,412